Precision BioSciences, Inc. has taken an additional step toward carving out a role for its off-the-shelf CAR-T PBCAR0191 as a treatment option for people who have relapsed after receiving autologous CAR-T with data showing a high response rate and durability in that population.
The company announced 8 June Phase I/IIa data for the allogeneic CAR-T cell therapy candidate in 11 evaluable patients with aggressive non-Hodgkin’s lymphoma (NHL) whose disease had relapsed after receiving autologous CAR-T and who were heavily
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?